On Thursday, AstraZeneca AZN will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release.
Earnings and Revenue
AstraZeneca EPS is expected to be around 29 cents, according to sell-side analysts. Sales will likely be near $5.09 billion.
The analyst consensus estimate would represent a 66.67 percent decline in the company's EPS figure. Revenue would be up 0.77 percent from the year-ago period. The company's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | 0.35 | 0.45 | 0.55 | 0.44 |
| EPS Actual | 0.48 | 1.3 | 1.12 | 0.87 |
Stock Performance
Over the last 52-week period, shares are up 9.9 percent. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The popular rating by analysts on AstraZeneca stock is a Neutral. The strength of this rating has risen over the past 90 days.
Conference Call
AstraZeneca's Q2 conference call is scheduled to begin at 8:00 a.m. ET and can be accessed here: https://www.astrazeneca.com/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
